Development of 225Ac/213Bi generator based on α-ZrP-PAN composite for targeted alpha therapy.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F24%3A00375453" target="_blank" >RIV/68407700:21340/24:00375453 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.nucmedbio.2024.108909" target="_blank" >https://doi.org/10.1016/j.nucmedbio.2024.108909</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.nucmedbio.2024.108909" target="_blank" >10.1016/j.nucmedbio.2024.108909</a>
Alternative languages
Result language
angličtina
Original language name
Development of 225Ac/213Bi generator based on α-ZrP-PAN composite for targeted alpha therapy.
Original language description
Background: Radioligand therapy using alpha emitters has gained more and more prominence in the last decade. Despite continued efforts to identify new appropriate radionuclides, the combination of 225Ac/213Bi remains among the most promising. Bismuth-213 has been employed in clinical trials in combination with appropriate vectors to treat patients with various forms of cancer, such as leukaemia, bladder cancer, neuroendocrine tumours, melanomas, gliomas, or lymphomas. However, the half-life of 213Bi (T1/2 = 46 min) implies that its availability for clinical use is limited to hospitals possessing a 225Ac/213Bi radionuclide generator, which is still predominantly scarce. We investigated a new Ac/Bi generator system based on using the composite sorbent α-ZrP-PAN (zirconium(IV) phosphate as active component and polyacrylonitrile as matrix). The developed 225Ac/213Bi generator was subjected to long-term testing after its development. The elution profile was determined and the elution yield, the contamination of the eluate with the parent 225Ac and the contamination of the eluate with the column material were monitored over time. Results: The high activity (75 MBq of parent 225Ac) generator with a length of 75 mm and a diameter of 4 mm containing the composite sorbent α-ZrP-PAN with a particle size of 0.8 to 1.0 mm as the stationary phase, eluted with a mixture of 10 mM DTPA in 5 mM nitric acid, provided 213Bi with yields ranging from 77 % to 96 % in 2.8 mL of eluate, with parent 225Ac contamination in the order of 10-3 %, up to twenty days of use. Conclusion: All the results of the monitored parameters indicate that the composite sorbent α-ZrP-PAN based separation system for the elution of 213Bi is a very promising and functional solution.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10402 - Inorganic and nuclear chemistry
Result continuities
Project
<a href="/en/project/TJ04000129" target="_blank" >TJ04000129: Separation of radionuclides for targeted alpha particle therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Nuclear Medicine and Biology
ISSN
0969-8051
e-ISSN
1872-9614
Volume of the periodical
132-133
Issue of the periodical within the volume
132-133
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
6
Pages from-to
1-6
UT code for WoS article
001227429300001
EID of the result in the Scopus database
2-s2.0-85189953696